Skip to main content
SpringerLink
Log in

Consider systemic therapy for chronic, refractory or severe cutaneous small-vessel vasculitis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Cutaneous small-vessel vasculitis (CSVV) typically presents as symmetrical palpable lesions on the lower extremities. Treatment options for CSVV depend on the severity and chronicity of the disease, presence of systemic involvement and identification of causal factors. Conservative management is recommended for first-episode CSVV, with the removal or treatment of any causes. A number of systemic treatments are used to treat recurrent, chronic or severe disease, despite the lack of clinical evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Goeser MR, Laniosz V, Wetter DA. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. Am J Clin Dermatol. 2014;15(4):299–306.

    Article  PubMed  Google Scholar 

  2. Piette WW. The differential diagnosis of purpura from a morphologic perspective. Adv Dermatol. 1994;9:3–23.

    PubMed  CAS  Google Scholar 

  3. Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006;45(1):3–13.

    Article  PubMed  Google Scholar 

  4. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48(3):311–40.

    Article  PubMed  Google Scholar 

  5. Lotti T, Ghersetich I, Comacchi C, et al. Cutaneous small-vessel vasculitis. J Am Acad Dermatol. 1998;39(5 Pt 1):667–87.

    Article  PubMed  CAS  Google Scholar 

  6. Fett N. Management of adults with idiopathic cutaneous small vessel vasculitis. Topic 13785 Version 5.0. 2014. http://www.uptodate.com/contents/management-of-adults-with-idiopathic-cutaneous-small-vessel-vascuilitis. Accessed 2014.

  7. Kinney MA, Jorizzo JL. Small-vessel vasculitis. Dermatol Ther. 2012;25(2):148–57.

    Article  PubMed  Google Scholar 

  8. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol. 1985;13(2 Pt 1):193–200.

    Article  PubMed  CAS  Google Scholar 

  9. Asherson RA, Buchanan N, Kenwright S, et al. The normocomplementemic urticarial vasculitis syndrome: report of a case and response to colchicine. Clin Exp Dermatol. 1991;16(6):424–7.

    Article  PubMed  CAS  Google Scholar 

  10. Ruiz Villaverde R, Blasco Melguizo J, Martin Sanchez MC, et al. Annular leucocytoclastic vasculitis: response to dapsone. J Eur Acad Dermatol Venereol. 2002;16(5):544–6.

    Article  PubMed  CAS  Google Scholar 

  11. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis: report of three cases. J Am Acad Dermatol. 1987;16(4):772–8.

    Article  PubMed  CAS  Google Scholar 

  12. Sais G, Vidaller A, Jucgla A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis: results of a prospective, randomized controlled trial. Arch Dermatol. 1995;131(12):1399–402.

    Article  PubMed  CAS  Google Scholar 

  13. Haeberle MT, Adams WB, Callen JP. Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol. 2012;148(8):887–8.

    Article  PubMed  Google Scholar 

  14. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol. 2000;143(6):1324.

    Article  PubMed  CAS  Google Scholar 

  15. Lunardi C, Bambara LM, Biasi D, et al. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol. 1992;10(2):131–5.

    PubMed  CAS  Google Scholar 

  16. Ferri C, Pietrogrande M, Cecchetti R, et al. Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med. 1989;87(5):519–24.

    Article  PubMed  CAS  Google Scholar 

  17. Lopez LR, Davis KC, Kohler PF, et al. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 1984;73(5 Pt 1):600–3.

    Article  PubMed  CAS  Google Scholar 

  18. Chung L, Funke AA, Chakravarty EF, et al. Successful use of rituximab for cutaneous vasculitis. Arch Dermatol. 2006;142(11):1407–10.

    Article  PubMed  Google Scholar 

  19. Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Marzano AV, Borghi A, Meroni PL, et al. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity. 2014;47(3):146–53.

    Article  PubMed  CAS  Google Scholar 

  21. Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20(1):213–27.

    Article  PubMed  Google Scholar 

  22. Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol. 2000;143(2):447–9.

    Article  PubMed  CAS  Google Scholar 

  23. Sais G, Vidaller A, Servitje O, et al. Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin. J Allergy Clin Immunol. 1996;98(1):232–3.

    Article  PubMed  CAS  Google Scholar 

  24. Turner AN, Whittaker S, Banks I, et al. Plasma exchange in refractory cutaneous vasculitis. Br J Dermatol. 1990;122(3):411–5.

    Article  PubMed  CAS  Google Scholar 

  25. Marzano AV, Vezzoli P, Berti E. Skin involvement in cutaneous and systemic vasculitis. Autoimmun Rev. 2013;12(4):467–76.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from the American Journal of Clinical Dermatology 2014;15(4):299–306 [1] by salaried/contracted employees of Adis/Springer. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Consider systemic therapy for chronic, refractory or severe cutaneous small-vessel vasculitis. Drugs Ther Perspect 30, 352–355 (2014). https://doi.org/10.1007/s40267-014-0151-3

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-014-0151-3

    Search

    Navigation